Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Takashi Kadowaki, Joakim Isendahl, Usman Khalid, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 3, pp. 193-206
Closed Access | Times Cited: 183

Showing 1-25 of 183 citing articles:

Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 231
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Eduardo Grunvald, Raj Shah, Rubén Hernáez, et al.
Gastroenterology (2022) Vol. 163, Iss. 5, pp. 1198-1225
Open Access | Times Cited: 126
Semaglutide for the treatment of overweight and obesity: A review
Natasha C. Bergmann, Melanie J. Davies, Ildiko Lingvay, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 18-35
Open Access | Times Cited: 106
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 103
New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J. Aronne, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2058-2072
Closed Access | Times Cited: 85
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Yamin Shu, Xu‐Cheng He, Pan Wu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 73
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
Ildiko Lingvay, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
Obesity (2022) Vol. 31, Iss. 1, pp. 111-122
Open Access | Times Cited: 73
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 69
Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk
Robert Wilson, Dhruvi Lathigara, Devesh Kaushal
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6192-6192
Open Access | Times Cited: 65
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
Femin Prasad, Riddhita De, Vittal Korann, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 54
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden, Ariana M. Chao, Molly Moore, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 4, pp. 453-473
Open Access | Times Cited: 54
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
Simon Kloock, Christian G. Ziegler, Ulrich Dischinger
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108549-108549
Open Access | Times Cited: 48
Medications for Obesity
Kimberly A. Gudzune, Robert F. Kushner
JAMA (2024) Vol. 332, Iss. 7, pp. 571-571
Closed Access | Times Cited: 40
Metabolic syndrome
Ian J. Neeland, Soo Lim, André Tchernof, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 39
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Yiming Mu, Xiao-lei Bao, Freddy G. Eliaschewitz, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 184-195
Closed Access | Times Cited: 38
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal, Harold Bays, Sébastien Czernichow, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 17, pp. 1573-1583
Closed Access | Times Cited: 34
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 29
Cardiometabolic risk factors and neurodegeneration: a review of the mechanisms underlying diabetes, obesity and hypertension in Alzheimer’s disease
Vijay Patel, Paul Edison
Journal of Neurology Neurosurgery & Psychiatry (2024) Vol. 95, Iss. 6, pp. 581-589
Open Access | Times Cited: 24
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Barbara McGowan, Jens Meldgaard Bruun, Matt Capehorn, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 9, pp. 631-642
Closed Access | Times Cited: 21
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Daniel J. Drucker
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 338-353
Open Access | Times Cited: 19
Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
Camille Lupiañez-Merly, Saam Dilmaghani, Kia Vosoughi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 4, pp. 475-491
Closed Access | Times Cited: 18
Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Xin‐Hui Pan, B.C. Tan, Yip Han Chin, et al.
Obesity (2024) Vol. 32, Iss. 5, pp. 840-856
Closed Access | Times Cited: 18
Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
Zeyu Xie, Sensen Yang, Weishang Deng, et al.
Clinical Epidemiology (2022) Vol. Volume 14, pp. 1463-1476
Open Access | Times Cited: 54
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Xueqin Gao, Xiaoli Hua, Xu Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 52
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top